ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ACTHAR gel has efficacy in the treatment of cutaneous sarcoidosis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070

Sarcoidosis, Pulmonary

COMPLETED PHASE4

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017

Sarcoidosis Pulmonary Sarcoidosis

UNKNOWN PHASE4

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

NCT00731757

Sarcoidosis Cutaneous Sarcoidosis

WITHDRAWN PHASE2

A Study of Adalimumab to Treat Sarcoidosis of the Skin

NCT00274352

Sarcoidosis

COMPLETED PHASE2

An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use

NCT01132235

Psoriasis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sarcoidosis is a multisystem granulomatous disease of unknown cause. Although sarcoidosis most commonly affects the lung3, it may affect any organ. Although corticosteroids are recognized as the drug of choice for sarcoidosis, ACTH is the only drug that is FDA-approved for this disorder. However, there is limited data on the efficacy of ACTH for this condition.

Presently, corticosteroids as considered the drug of choice for the treatment of cutaneous sarcoidosis. However, ACTHER GEL not only has obvious anti-inflammatory effects by resulting in corticosteroid production, but it may also activate melanocortin receptors. The melanocortin system has powerful anti-inflammatory properties that may be beneficial in the treatment of cutaneous sarcoidosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis Cutaneous Sarcoidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACTHAR Gel 40 units twice weekly

ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.

Group Type EXPERIMENTAL

ACTHAR Gel 40 units twice weekly

Intervention Type DRUG

ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.

ACTHAR Gel 80 units twice weekly

ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.

Group Type EXPERIMENTAL

ACTHAR Gel 80 units twice weekly.

Intervention Type DRUG

ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACTHAR Gel 40 units twice weekly

ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.

Intervention Type DRUG

ACTHAR Gel 80 units twice weekly.

ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must have biopsy-proven sarcoidosis.
2. a) Patients with active cutaneous sarcoidosis and two active lesions on stable therapy or no therapy for at least two months AND/OR b) Patients with active cutaneous sarcoidosis and lupus pernio lesions on stable therapy or no therapy for at least two months. A maximum of 5 patients may be enrolled fulfilling criterion b) above.
3. Both lesions must have a SASI induration score of \> 1 and a SASI induration + erythema score of \> 2.
4. If two lesions are present, one must be \> 1cm in diameter and the subject must be willing to have it biopsied. The second lesion must be at least 0.5 cm in diameter.
5. If a subject has only lupus pernio facial lesions, one needs to be at least 0.5 cm in diameter.

Exclusion Criteria

1. Previous toxic or allergic reaction to ACTHAR gel
2. The presence of another skin condition in addition to sarcoidosis that would interfere with the assessment of the sarcoidosis skin lesions.
3. Uncontrolled hypertension.
4. Uncontrolled diabetes.
5. Active infection.
6. A medical condition that, in the opinion of the investigator would place the subject at significant risk by administering ACTHAR gel.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No